ChemoCentryx Inc. (NASDAQ:CCXI) went down by -6.44% from its latest closing price compared to the recent 1-year high of $70.29. The company’s stock price has collected 0.52% of gains in the last five trading sessions. Press Release reported on 01/04/22 that ChemoCentryx to Present at Two Upcoming Investor Conferences
Is It Worth Investing in ChemoCentryx Inc. (NASDAQ :CCXI) Right Now?
Plus, the 36-month beta value for CCXI is at 1.76. Opinions of the stock are interesting as 7 analysts out of 8 who provided ratings for ChemoCentryx Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $72.38, which is $35.78 above the current price. CCXI currently public float of 57.13M and currently shorts hold a 9.78% ratio of that float. Today, the average trading volume of CCXI was 4.70M shares.
CCXI’s Market Performance
CCXI stocks went up by 0.52% for the week, with a monthly drop of 0.00% and a quarterly performance of -4.71%, while its annual performance rate touched -38.49%. The volatility ratio for the week stands at 8.45% while the volatility levels for the past 30 days are set at 6.42% for ChemoCentryx Inc.. The simple moving average for the period of the last 20 days is 2.05% for CCXI stocks with a simple moving average of 40.02% for the last 200 days.
Analysts’ Opinion of CCXI
Many brokerage firms have already submitted their reports for CCXI stocks, with SVB Leerink repeating the rating for CCXI by listing it as a “Outperform.” The predicted price for CCXI in the upcoming period, according to SVB Leerink is $64 based on the research report published on October 11th of the previous year 2021.
JP Morgan, on the other hand, stated in their research note that they expect to see CCXI reach a price target of $38, previously predicting the price at $14. The rating they have provided for CCXI stocks is “Neutral” according to the report published on October 11th, 2021.
Raymond James gave a rating of “Strong Buy” to CCXI, setting the target price at $107 in the report published on October 08th of the previous year.
CCXI Trading at -0.67% from the 50-Day Moving Average
After a stumble in the market that brought CCXI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.93% of loss for the given period.
Volatility was left at 6.42%, however, over the last 30 days, the volatility rate increased by 8.45%, as shares surge +4.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.17% upper at present.
During the last 5 trading sessions, CCXI rose by +0.52%, which changed the moving average for the period of 200-days by -29.19% in comparison to the 20-day moving average, which settled at $35.95. In addition, ChemoCentryx Inc. saw 0.52% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at CCXI starting from Tyree James L, who sale 37,500 shares at the price of $35.02 back on Dec 17. After this action, Tyree James L now owns 15,275 shares of ChemoCentryx Inc., valued at $1,313,165 using the latest closing price.
Vifor (International) Ltd, the 10% Owner of ChemoCentryx Inc., sale 4,000,000 shares at $39.43 during a trade that took place back on Oct 12, which means that Vifor (International) Ltd is holding 5,194,085 shares at $157,720,000 based on the most recent closing price.
Stock Fundamentals for CCXI
Current profitability levels for the company are sitting at:
- -85.03 for the present operating margin
The net margin for ChemoCentryx Inc. stands at -85.31. The total capital return value is set at -20.53, while invested capital returns managed to touch -20.94. Equity return is now at value -34.80, with -25.00 for asset returns.
Based on ChemoCentryx Inc. (CCXI), the company’s capital structure generated 16.57 points at debt to equity in total, while total debt to capital is 14.22. Total debt to assets is 12.32, with long-term debt to equity ratio resting at 14.72. Finally, the long-term debt to capital ratio is 12.63.
When we switch over and look at the enterprise to sales, we see a ratio of 64.24, with the company’s debt to enterprise value settled at 0.02. The receivables turnover for the company is 376.18 and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.56.